Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer

NCT ID: NCT00957112

Last Updated: 2013-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Acupuncture may help relieve fatigue caused by breast cancer. It is not yet known whether acupuncture is more effective than self-acupuncture in managing fatigue in women with breast cancer.

PURPOSE: This randomized phase III trial is studying acupuncture to see how well it works compared with self-acupuncture in managing cancer-related fatigue in women who have received chemotherapy for stage I, stage II, or stage IIIA breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Assess the efficacy of a course of acupuncture in the management of cancer-related fatigue in a homogeneous sample of women with stage I, II, or IIIA breast cancer who have completed adjuvant chemotherapy.
* Assess the efficacy of self-acupuncture in comparison to therapist-administered acupuncture in sustaining, in the longer term, any effects observed with a 6-week course of acupuncture in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to study center and fatigue score (low vs moderate vs severe). Patients are randomized at 3:1 ratio (arm I: arm II) to 1 of 2 treatment arms.

* Arm I (experimental): Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
* Arm II (control): Patients undergo standard care. They also receive written information about fatigue as in arm I.

After 6 weeks, patients in arm I are again randomized to 1 of 3 arms.

* Arm A: Patients receive treatment as in arm I for 4 more weeks.
* Arm B: Patients receive treatment as in arm II for 4 more weeks.
* Arm C: Patients learn to self-acupuncture and do so weekly for 4 more weeks. All patients complete questionnaires on fatigue, hospital anxiety and depression, quality of life, and use of complementary therapies at baseline and periodically during study. Patient's sociodemographic and treatment characteristic records are also reviewed.

After completion of study therapy, patients are followed up periodically for 18 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety Disorder Breast Cancer Depression Fatigue

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

anxiety disorder depression fatigue stage IA breast cancer stage IB breast cancer stage II breast cancer stage IIIA breast cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.

Group Type EXPERIMENTAL

acupuncture therapy

Intervention Type PROCEDURE

Patients undergo therapist-acupuncture with or without self-acupuncture

Arm II

Patients receive standard care. They also receive written information about fatigue as in arm I.

Group Type NO_INTERVENTION

standard follow-up care

Intervention Type PROCEDURE

Patients receive standard care

Arm A

Patients receive treatment as in arm I for 4 more weeks.

Group Type EXPERIMENTAL

acupuncture therapy

Intervention Type PROCEDURE

Patients undergo therapist-acupuncture with or without self-acupuncture

Arm B

Patients receive standard care as in arm II for 4 more weeks.

Group Type NO_INTERVENTION

standard follow-up care

Intervention Type PROCEDURE

Patients receive standard care

Arm C

Patients learn to self-acupuncture and do so weekly for 4 more weeks.

Group Type EXPERIMENTAL

acupuncture therapy

Intervention Type PROCEDURE

Patients undergo therapist-acupuncture with or without self-acupuncture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acupuncture therapy

Patients undergo therapist-acupuncture with or without self-acupuncture

Intervention Type PROCEDURE

standard follow-up care

Patients receive standard care

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of breast cancer

* Stage I, II, or IIIA disease
* Completed prior chemotherapy for ≥ 1 month and up to 5 years

* No needling on the ipsilateral arm of patients who have undergone axillary dissection
* No needling on the lymphedematous limbs
* Score of ≥ 5 on a 0-10 single-item screening fatigue scale, where 0 is no fatigue at all and 10 is extremely fatigued
* Hormone receptor status not specified

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 6 months
* Menopausal status not specified
* Platelet count ≥ 50,000/mm\^3
* Hemoglobin ≥ 10 g/dL
* Hematocrit ≥ 30%
* Not pregnant
* No needle phobia
* No co-morbidity with any of the following:

* Bleeding disorder
* Thyroid dysfunction

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No planned concurrent chemoradiotherapy
* No concurrent steroids
* No concurrent epoetin alfa or transfusion for anemia
* No other concurrent complementary therapies
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manchester

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alex Molassiotis, MD

Role: PRINCIPAL_INVESTIGATOR

University of Manchester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Manchester

Manchester, England, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder WD, Filshie J, Ream E, Eaton D, Richardson A. A randomized, controlled trial of acupuncture self-needling as maintenance therapy for cancer-related fatigue after therapist-delivered acupuncture. Ann Oncol. 2013 Jun;24(6):1645-52. doi: 10.1093/annonc/mdt034. Epub 2013 Feb 21.

Reference Type DERIVED
PMID: 23436910 (View on PubMed)

Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J, Ream E, Richardson A. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol. 2012 Dec 20;30(36):4470-6. doi: 10.1200/JCO.2012.41.6222. Epub 2012 Oct 29.

Reference Type DERIVED
PMID: 23109700 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UM-ASA

Identifier Type: -

Identifier Source: secondary_id

EU-20970

Identifier Type: -

Identifier Source: secondary_id

CDR0000649750

Identifier Type: -

Identifier Source: org_study_id